You are here: Home » Companies » News
Business Standard

Glenmark Pharma gets USFDA nod for seizure treatment drug

Shares of Glenmark Pharmaceuticals were trading 1.02% higher at Rs 656.10 apiece on the BSE

Glenmark Pharma  |  Glenmark  |  Drugs

Press Trust of India  |  New Delhi 

Photo: Reuters
Photo: Reuters

Pharmaceuticals has received a tentative nod from the US health regulator for Topiramate extended release capsules, used to treat certain types of seizures.

The approved product is a generic version of Upsher-Smith Laboratories, LLC's QUDEXY XR extended release capsules.

Pharmaceuticals Inc USA has been granted tentative approval by the Food and Drug Administration for Topiramate extended release capsules in the strength of 25 mg, 50 mg, 100 mg, 150 mg and 200 mg, the company said in a BSE filing on Thursday.

Quoting IQVIA sales data for the 12-month period ended November 2018, Pharmaceuticals said, QUDEXY XR extended release capsules market achieved annual sales of approximately $84 million.

The company's current portfolio consists of 148 products authorised for distribution in the US market and 54 abbreviated new drug applications (ANDAs) pending approval with the

Shares of were trading 1.02 per cent higher at Rs 656.10 apiece on the BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, January 24 2019. 10:35 IST